-$0.57 EPS Expected for NanoString Technologies Inc (NASDAQ:NSTG) This Quarter

Analysts expect NanoString Technologies Inc (NASDAQ:NSTG) to post earnings of ($0.57) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for NanoString Technologies’ earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.49). NanoString Technologies reported earnings of ($0.56) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 1.8%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that NanoString Technologies will report full-year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.39) to ($2.33). For the next financial year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.41) to ($1.75). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover NanoString Technologies.

NanoString Technologies (NASDAQ:NSTG) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). NanoString Technologies had a negative return on equity of 118.03% and a negative net margin of 68.16%. The company had revenue of $30.35 million during the quarter, compared to analysts’ expectations of $29.00 million.



A number of equities research analysts recently commented on NSTG shares. Zacks Investment Research lowered shares of NanoString Technologies from a “hold” rating to a “sell” rating in a report on Thursday, September 19th. BidaskClub downgraded shares of NanoString Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $26.25.

In other news, CFO K Thomas Bailey sold 35,625 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $25.24, for a total value of $899,175.00. Following the transaction, the chief financial officer now owns 35,625 shares in the company, valued at approximately $899,175. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mary Tedd Allen sold 64,333 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $1,923,556.70. Following the completion of the transaction, the senior vice president now owns 55,433 shares in the company, valued at approximately $1,657,446.70. The disclosure for this sale can be found here. Insiders have sold a total of 185,211 shares of company stock worth $5,008,655 in the last 90 days. Company insiders own 5.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. River & Mercantile Asset Management LLP bought a new stake in NanoString Technologies during the 2nd quarter worth approximately $1,604,000. Harbourvest Partners LLC purchased a new stake in NanoString Technologies during the 2nd quarter valued at approximately $1,692,000. Rehmann Capital Advisory Group grew its holdings in NanoString Technologies by 184.2% during the 2nd quarter. Rehmann Capital Advisory Group now owns 41,931 shares of the biotechnology company’s stock valued at $1,273,000 after buying an additional 27,175 shares in the last quarter. United Services Automobile Association purchased a new stake in NanoString Technologies during the 2nd quarter valued at approximately $228,000. Finally, Nuveen Asset Management LLC purchased a new stake in NanoString Technologies during the 2nd quarter valued at approximately $18,453,000. Institutional investors own 99.85% of the company’s stock.

Shares of NSTG traded down $1.31 during mid-day trading on Friday, reaching $21.50. The company’s stock had a trading volume of 740,870 shares, compared to its average volume of 527,489. The stock has a market cap of $863.06 million, a PE ratio of -7.73 and a beta of 1.22. The company has a current ratio of 5.21, a quick ratio of 4.76 and a debt-to-equity ratio of 1.27. NanoString Technologies has a 52 week low of $13.26 and a 52 week high of $34.78. The company’s fifty day moving average price is $24.59 and its two-hundred day moving average price is $26.64.

About NanoString Technologies

NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.

Read More: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on NanoString Technologies (NSTG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.